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Abstract Previously, we showed that 3% (31/1032)of asymptomatic healthcare workers (HCWs)
from a large teaching hospital in Cambridge, UK, tested positive for SARS-CoV-2 in April 2020.
About 15% (26/169) HCWs with symptoms of coronavirus disease 2019 (COVID-19) also tested
positive for SARS-CoV-2 (Rivett et al., 2020). Here, we show that the proportion of both
asymptomatic and symptomatic HCWs testing positive for SARS-CoV-2 rapidly declined to near-
zero between 25th April and 24th May 2020, corresponding to a decline in patient admissions with
COVID-19 during the ongoing UK ‘lockdown’. These data demonstrate how infection prevention
and control measures including staff testing may help prevent hospitals from becoming
independent ‘hubs’ of SARS-CoV-2 transmission, and illustrate how, with appropriate precautions,
organizations in other sectors may be able to resume on-site work safely.
Introduction
The role of nosocomial transmission of SARS-CoV-2 has been highlighted by recent evidence sug-
gesting that 20% of SARS-CoV-2 infections among patients in UK hospitals and up to 89% of infec-
tions among HCWs may have originated in hospitals (Evans et al., 2020; Iacobucci, 2020). Since the
introduction of ‘lockdown’ in the UK, community transmission rates of SARS-CoV-2 have generally
declined (Public Health England (PHE), 2020). Conversely, concerns have been raised that hospitals
could become independent ‘hubs’ for ongoing SARS-CoV-2 transmission between patients and
HCWs, which would effectively prolong the epidemic (Iacobucci, 2020). In this context,
the evolution of the epidemic curves of a hospital’s symptomatic and asymptomatic workforce has
not been well described.
We recently initiated a comprehensive HCW screening programme for SARS-CoV-2 in a large
teaching hospital in Cambridge, UK. Over a 3-week period from 6th to 24th April 2020, 3% (31/
1032) HCWs in the asymptomatic screening arm, 15.4% (26/169) HCWs in the symptomatic screen-
ing arm, and 7.7% (4/52) contacts in the symptomatic household contact screening arm tested posi-
tive for SARS-CoV-2 (Rivett et al., 2020). Our data from the asymptomatic screening arm were
consistent with the results of Shields et al. (Shields et al., 2020). Over the next 4 weeks from 25th
April to 24th May 2020, we performed a further 3388 additional tests. Here, we present these longi-
tudinal data, in the context of the hospital patient population and wider local community.
Results
Testing for SARS-CoV-2 RNA was performed with real-time RT-PCR using throat and nose swab sam-
ples of HCWs from Cambridge University Hospitals NHS Foundation Trust (CUHNFT) and their
symptomatic household contacts. Over the new study period (25th April to 24th May 2020), 2611
additional tests were performed in the HCW asymptomatic screening arm, 555 additional tests in
the HCW symptomatic screening arm, and 216 additional tests in the HCW household contact
screening arm. A further six tests did not have a clearly recorded arm of origin. Over the entire study
period, the median age of HCWs and their household contacts was 36.5 and 35.5 years, respectively.
About 68.4% were female and 31.6% were male. Of the individuals testing positive over the entire
study period, the median age of HCWs and their household contacts was 32 and 47
years, respectively. About 77.9% of all positive tests were from females and 22.1% from males.
Table 1 summarizes the total number of HCWs testing positive through either arm of the screening
programme, according to the job role. A comparison of the proportions of hospital employees from
each job role that tested positive through the HCW symptomatic screening arm revealed no statisti-
cally significant difference (Pearson’s chi-square test p=0.419). Reasonable comparison of the pro-
portions testing positive through the HCW asymptomatic screening arm was not possible due to
non-random sampling of different areas of the hospital, meaning some job roles had been more fre-
quently targeted for asymptomatic screening than others.
Between 25th April and 24th May 2020, a total of 34 new positive tests were reported. In the
HCW symptomatic and HCW symptomatic household contact screening arms combined (reflecting
all individuals with self-reported symptoms at the time of testing), 13/771 (1.7%) tests were positive,
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which was significantly lower than 30/221 (13%) in the original study period (Fisher’s exact test
p<0.0001). In the HCW asymptomatic screening arm, 21/2611 (0.8%) tests were positive, which
again was significantly lower than 31/1032 (3%) in the original study period (Fisher’s exact test
p<0.0001). As we previously observed (Rivett et al., 2020), individuals captured in the HCW asymp-
tomatic screening arm were generally asymptomatic at the time of screening; however, these indi-
viduals could be divided into subgroups. In the first subgroup, 8/21 (38%) HCWs had no symptoms
at all. Of these, 5/8 (63%) remained entirely asymptomatic 5–7 weeks after their positive test,
whereas 2/8 (25%) developed symptoms 24–48 hr after testing. One HCW could not be contacted
to obtain further history. In the second subgroup, 6/21 (29%) had retrospectively experienced some
symptoms prior to screening. Of these, 5/6 (83%) had symptoms with a high pre-test probability of
COVID-19 (Rivett et al., 2020) commencing >7 days prior to screening, of whom 3/5 had appropri-
ately self-isolated then returned to work, and 1/5 was tested shortly after developing symptoms. 1/6
(17%) had symptoms with a low pre-test probability of COVID-19 (Rivett et al., 2020) commenc-
ing <7 days prior to screening and had not self-isolated. In the third subgroup, 7/21 (33%) were
detected through repeat sampling of HCW who previously tested positive. Of these, 4/7 (57%) were
tested to determine their suitability to return to work with severely immunocompromised/immuno-
suppressed patients, as dictated by UK national guidance (National Institute for Health and Care
Excellence (NICE), 2020). The remaining 3/7 (43%) were from HCWs tested incidentally for the sec-
ond time in the asymptomatic HCW screening programme. The median interval between serial posi-
tive tests was 16.5 days (IQR 9.5–19.5). All cases were attributable to prolonged SARS-CoV-2 RNA
detection from a single infection, rather than re-infection. Our approach to patients with repeatedly
positive SARS-CoV-2 PCR tests is described in the Methods.
The fraction of positive tests among the HCW asymptomatic, and HCW symptomatic and house-
hold contact screening groups combined varied over time (Figure 1A, Table 2). In particular, during
the last 2 weeks of the study period (11th to 24th May 2020), we identified only four positive SARS-
CoV-2 samples from 2016 tests performed, two from the HCW asymptomatic and two from the
HCW symptomatic/symptomatic household contact arms. This fall in positive HCW tests mirrored
the decline in both patients testing positive at CUHNFT and those tested throughout the wider
region (Figure 1B). Similar trends were observed in a smaller cohort study of HCWs in London
(Treibel et al., 2020).
In our original study between 6th and 24th April 2020, we described in detail two clusters of
HCW infections (Rivett et al., 2020). From 25th April to 24th May 2020, we detected one additional
cluster on a general medical ward with a separate area for patients with proven COVID-19 and
another area for those without. This was identified through targeted screening of the ward over a 24
hr period from 4th to 5th May 2020, in response to four staff testing positive through the HCW
symptomatic arm of the screening programme from 27th to 30th April 2020. Reactive screening of a
Table 1. Combined data for SARS-CoV-2 RNA positive HCWs by role and screening arm, from the present study and our previous
study (Rivett et al., 2020).
Difference in proportions of HCWs testing positive through the symptomatic screening arm was analysed using Pearson’s chi-square
test.
Role HCW asymptomatic screening arm HCW symptomatic screening arm Total number of hospital employees
Nurse 25 19 3621
Healthcare assistant 14 8 1734
Doctor 8 6 1871
Cleaners 2 3 560
Radiographer 2 1 217
Radiology support worker 0 1 35
Physiotherapist 1 0 116
Overall, 360 individuals underwent repeat testing, either as part of the asymptomatic screening programme, or for other reasons as previously described
(Rivett et al., 2020). The median turnaround time from sample arrival in the laboratory to final verification was 18 hr 45 min. Positive results were called
out on the same day, with negative results emailed within 24 hr.
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further 40 staff from the same ward identified a further three positive asymptomatic HCWs. In addi-
tion, a further two HCWs tested positive in an asymptomatic screen of 30 individuals from a closely
related clinical area (designated for non-COVID patients) on 6th May 2020.
Discussion
Our data demonstrate a dramatic fall in the prevalence of symptomatic and asymptomatic SARS-
CoV-2 infection among HCWs in our hospital during the study period. On average, the number of
secondary infections among HCWs arising from each infected HCW (effectively, the reproduction
number (R) for SARS-CoV-2 transmission between HCWs) must therefore be <1.
As well as an acquisition from other HCWs, infections among HCWs may also be acquired from
patients, as well as other individuals outside the hospital. Our study period coincided with a decline
in the rate of infection across our local community, and our data are consistent with a reduction in
transmission within the hospital, a reduction in community-based acquisition of infection by HCWs,
or (most likely) a combination of both. In the absence of detailed epidemiological data, it is not pos-
sible to formally differentiate between these possibilities or determine their relative effect sizes.
Nonetheless, our identification of HCW infection clusters in specific areas of the hospital highlighted
the potential for workplace acquisition of SARS-CoV-2, which may lead to self-sustaining outbreaks if
left uninterrupted (Rivett et al., 2020; Meredeth et al., 2020). For each of these clusters, timely
a) c) 
b) d) 
Figure 1. Trends in positive SARS-CoV-2 PCR tests among HCWs, hospital patients and the wider community over time. (a) Positive SARS-CoV-2 tests
for asymptomatic and symptomatic screening arms by week. (b) Total HCW SARS-CoV-2 tests in CUHNFT performed by week. (c) Total positive SARS-
CoV-2 patient tests in Cambridge University Hospital NHS Foundation Trust (CUHNFT) by week. (d) Total positive SARS-CoV-2 tests in the East of
England (EOE) by week.
The online version of this article includes the following source data for figure 1:
Source data 1. Source data for trends in SARS-CoV-2 PCR positive HCWs, hospital patients and individuals in the wider community.
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identification of HCW infection proved effective in terminating chains of hospital transmission
between staff, preventing ongoing nosocomial infection.
With the incidence of infection having fallen significantly in hospitalised patients, HCWs and the
wider community, many hospitals across the UK and further afield have been afforded precious time
to build the infrastructure necessary to establish comprehensive screening programmes in anticipa-
tion of a possible second epidemic peak. For hospitals already operating newly established screen-
ing programmes, the challenge now is to up-scale to the point that screening can occur at a
frequency that permits pre-symptomatic capture of as close to 100% of all new infections as possi-
ble. This approach will enable staff to be removed from the workplace at the time of peak infectivity
(He et al., 2020). The minimum screening frequency required needs to be carefully modelled, with
recent estimates suggesting the need for weekly testing to prevent 16–33% of onward transmission
from HCWs, depending on the time taken for results to be reported, and another study estimating
the need for daily screening to prevent 65% of HCW-to-HCW transmission events (Evans et al.,
2020; Grassly et al., 2020). In practice, we have observed good results in our hospital with a current
frequency of asymptomatic screening every 2–4 weeks. Those being screened are prioritised by
anticipated ward-based exposure to COVID-19, with additional targeted screens triggered by excess
staff sickness or the identification of symptomatic cases on specific wards (Rivett et al., 2020). In
addition to asymptomatic screening, testing of symptomatic HCWs is essential for preventing exces-
sive erosion of the hospital workforce by self-isolation on the basis of symptoms alone, and testing
of symptomatic HCW household contacts negates the need for unnecessary self-quarantine periods
for co-habiting HCWs. We found uptake to the HCW symptomatic household contact screening arm
of our programme to be notably lower than the HCW symptomatic arm despite regular communica-
tions to advertise the service within CUHNFT. This lack of uptake may reflect a lack of awareness
that symptomatic non-HCWs were eligible for testing, provided they shared a household with a hos-
pital employee. Many non-hospital employees may also have been more inclined to attend national
testing centres or be less aware of the spectrum of COVID-19 symptoms.
Importantly, our data demonstrate that CUHNFT was not acting as an independent ‘hub’ for
ongoing COVID-19 transmission among HCWs. The absence of nosocomial transmission likely
reflects the combined efficacy of HCW testing, stringent prospective, and reactive infection preven-
tion and control measures, and appropriate social distancing among the workforce. These findings
should give reassurance to both hospital staff and patients that healthcare facilities remain safe pla-
ces to give and receive care. Furthermore, since CUHNFT, with approximately 11,000 staff members
(many of whom are based in the hospital) is a major regional employer, we predict that comparable
Table 2. Positive tests and total number of SARS-CoV-2 tests performed in each screening arm
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We previously described protocols for staff screening, sample collection, laboratory processing, and
results reporting in detail (Rivett et al., 2020). These methods remained unchanged throughout this
study period. Two parallel streams of entry into the testing programme included (i) HCW symptom-
atic, and HCW symptomatic household contact screening arms and (ii) an HCW asymptomatic
screening arm. In the former, any patient-facing or non-patient-facing HCW could voluntarily refer
themselves or a household contact, should they develop symptoms suggestive of COVID-19. In the
latter, HCWs could volunteer to take part in a rolling programme of testing for all patient-facing and
non-patient-facing staff working in defined clinical areas thought to be at risk of SARS-CoV-2 trans-
mission. Testing was performed (i) at temporary on-site ‘Pods’; (ii) via self-swabbing kits delivered to
HCWs in their area of work. All individuals in each arm of the programme performed a self-swab at
the back of the throat then the nasal cavity, followed by RNA extraction and amplification using real-
time RT-PCR (Sridhar et al., 2020). Cluster investigation was initiated when three or more HCWs
working in the same clinical area tested positive for SARS-CoV-2 in 1 week .
Management of HCW with repeat positive tests
Current National Institute for Health and Care Excellence (NICE) guidelines require a negative test
before returning to work with immunocompromised patients (National Institute for Health and
Care Excellence (NICE), 2020). In accordance with the UK national guidance, individuals with repeat
positive screens following a minimum period of 7 days self-isolation were advised to continue work-
ing if they were not scheduled to come into close contact with heavily immunocompromised
patients, provided they remained asymptomatic (UK Government, 2020). This approach to manag-
ing repeat positive screens is further supported by recent data from the Korea Centers for Disease
Control and Prevention, which showed no clear evidence of onward transmission to the contacts of
285 repeat-positive individuals, 108 of whom had samples taken for attempted viral culture, which
was universally unsuccessful (Korea Centers for Disease Control & Prevention (KCDC), 2020).
Additional small studies have also demonstrated an inability to culture virus from clinical samples
obtained later than 8 days after symptom onset, suggesting prolonged detection of viral RNA is
unlikely to indicate an ongoing risk of transmission (Wölfel et al., 2020; Bullard et al., 2020).
Data extraction and analysis
Swab result data for HCWs and patients were extracted directly from the hospital-laboratory inter-
face software, Epic (Verona, WI) and from SARS-CoV-2 point of care testing. Data for SARS-CoV-2
infections from the local community were extracted from Public Health England’s Data Dashboard
(Public Health England (PHE), 2020). Data were collated using Microsoft Excel, and figures pro-
duced with GraphPad Prism (GraphPad Software, La Jolla, CA). Fisher’s exact test was used to com-
pare the proportion of HCWs testing positive in this study period to that of our previous study
period (Rivett et al., 2020). Pearson’s chi-square test was used for comparison of the proportions of
HCWs testing positive in each job role.
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